Quick Answer
LianBio reported Cash and Equivalents of $79.22 million for fiscal year 2022.
LianBio Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $79.22M | -65.3% |
| 2021 | $228.18M | -10.3% |
| 2020 | $254.35M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $103.46M | +31.2% | -0.6% |
| June 30, 2023 | $104.06M | -22.5% | +1.7% |
| March 31, 2023 | $102.33M | -26.8% | +29.2% |
| December 31, 2022 | $79.22M | -65.3% | +0.5% |
| September 30, 2022 | $78.86M | -27.7% | -41.3% |
| June 30, 2022 | $134.33M | -5.8% | -3.9% |
| March 31, 2022 | $139.86M | -40.6% | -38.7% |
| December 31, 2021 | $228.18M | — | +109.3% |
- LianBio showed a decrease of -65.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2022 period, LianBio’s cash and equivalents has declined by 68.9% (from $254.35 million to $79.22 million).
- The most recent figure is from LianBio’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 28, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: